share_log

Aurinia Pharmaceuticals | 8-K: Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS ® Growth and AUR200 Development

Aurinia Pharmaceuticals | 8-K: Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS ® Growth and AUR200 Development

Aurinia Pharmaceuticals | 8-K:Aurinia Pharmicals 公布了 2024 年第三季度和九个月的财务和经营业绩,宣布进行战略重组,以进一步关注 LUPKYNIS® 的持续增长和 AUR200 的发展
美股SEC公告 ·  2024/11/07 19:18
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息